Browsing by Author "Vidal Barrull, Joana"

Sort by: Order: Results:

  • Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
    Van Emburgh, Beth O.; Vidal Barrull, Joana; Bellosillo Paricio, Beatriz; Albanell Mestres, Joan; Montagut Viladot, Clara; Bardelli, Alberto (Nature Publishing Group, 2016)
    Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of ...
  • ctDNA to detect minimal residual disease in pancreatic cancer: moving into clinical trials
    Montagut Viladot, Clara; Vidal Barrull, Joana (Oxford University Press, 2019)
  • ctDNA to guide adjuvant therapy in localized colorectal cancer (CRC)
    Masfarré, Laura; Vidal Barrull, Joana; Fernández Rodríguez, M. Concepción; Montagut Viladot, Clara (MDPI, 2021)
    Currently, the standard treatment for patients with localized colorectal cancer (CRC) includes surgical resection followed by adjuvant chemotherapy based on clinicopathological features. Recurrence risk stratification in ...
  • Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
    Casadevall Aguilar, David; Vidal Barrull, Joana; Gallardo Hernández, Fernando; Zuccarino, Flavio; Arumí, Montserrat; Dalmases Massegú, Alba, 1982-; Bellosillo Paricio, Beatriz; Montagut Viladot, Clara (BioMed Central, 2016)
    BACKGROUND: Approximately 50 % of malignant melanomas harbor activating point mutations in the BRAF gene. Typically, these mutations result in the substitution of the amino acid valine at codon 600 of the gene, and 90-95 ...
  • Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations
    Brammeld, Jonathan S.; Dalmases Massegú, Alba, 1982-; Bellosillo Paricio, Beatriz; Vidal Barrull, Joana; Montagut Viladot, Clara; McDermott, Ultan (Cold Spring Harbor Laboratory Press (CSHL Press), 2017)
    Drug resistance is an almost inevitable consequence of cancer therapy and ultimately proves fatal for the majority of patients. In many cases, this is the consequence of specific gene mutations that have the potential to ...
  • High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer
    Bessa Caserras, Xavier; Vidal Barrull, Joana; Balboa, J. C.; Márquez, Carmen; Duenwald, Sven J.; He, Y.; Raymond, Victoria M.; Faull, Iris; Burón, Andrea; Álvarez-Urturi, Cristina; Castells, Xavier; Bellosillo Paricio, Beatriz; Montagut Viladot, Clara (Elsevier, 2023)
    Background: Detection of circulating tumor DNA (ctDNA) is a minimally invasive and convenient blood-based screening strategy that may increase effectiveness of colorectal cancer (CRC) screening. Patients and methods: A ...
  • Hypersensitivity reaction caused by folinic acid administration: a case report and literature review.
    Florit-Sureda, Marta; Conde Estévez, David; Vidal Barrull, Joana; Montagut Viladot, Clara (Maney Publishing, 2016)
    5-Fluorouracil (5-FU) is combined with folinic acid (FA) for enhancing its cytotoxic effects in the colon cancer chemotherapy treatment. Folinic acid has rarely been involved in hypersensitivity reactions. Here, we report ...
  • Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study
    Martinelli, Erika; Cremolini, Chiara; Mazard, Thibault; Vidal Barrull, Joana; Virchow, I.; Tougeron, David; Cuyle, Pieter-Jan; Chibaudel, Benoist; Kim, Stefano; Ghanem, Ismael; Asselain, Bernard; Castagné, Coline; Zkik, A.; Khan, S.; Arnold, Dirk (Elsevier, 2022)
    Background: BRAFV600E mutations occur in 8%-12% of metastatic colorectal cancer (mCRC) cases and are associated with poor survival. European guidelines recommend combination (doublet or triplet) chemotherapy plus bevacizumab ...
  • ROS1 copy number alterations are frequent in non-small cell lung cancer
    Clavé Safont, Sergi; Gimeno Beltran, Javier; Muñoz-Mármol, Ana M.; Vidal Barrull, Joana; Reguart, Noemí; Carcereny, Enric; Pijuan Andujar, Lara; Menendez Romero, Silvia; Taus García, Álvaro; Mate, José Luís; Serrano Figueras, Sergi; Albanell Mestres, Joan; Espinet Solà, Blanca; Arriola Aperribay, Edurne; Salido Galeote, Marta (Impact Journals, 2014)
    OBJECTIVES: We aimed to determine the prevalence and partners of ROS1 rearrangements, to explore the correlation between FISH and IHC assays, and to investigate clinical implications of ROS1 copy number alterations (CNAs). ...
  • The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
    Sanchez Martin, Francisco Javier; Bellosillo Paricio, Beatriz; Gelabert-Baldrich, Mariona; Dalmases Massegú, Alba, 1982-; Cañadas Castillo, Israel, 1984-; Vidal Barrull, Joana; Martinez, Alejandro; Argiles, Guillem; Visa Turmo, Laura; Arpí Llucià, Oriol; Iglesias García, Mar; Rovira Guerín, Ana; Albanell Mestres, Joan; Tabernero Cartula, Josep; Montagut Viladot, Clara (American Association for Cancer Research, 2016)
    PURPOSE: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, patients ultimately develop disease progression, often ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking